PF-4708671

Name: PF-4708671
Brand: Selleck Chemicals
SKU: S2163
Rating: 5 (33 reviews)

For research use only.

Licensed and Manufactured by Pfizer Catalog No.S2163

33 publications

CAS No. 1255517-76-0

PF-4708671 is a cell-permeable inhibitor of p70 ribosomal S6 kinase (S6K1 isoform) with K_i/IC50 of 20 nM/160 nM in cell-free assays, 400-fold greater selectivity for S6K1 than S6K2, and 4- and >20-fold selectivity for S6K1 than MSK1 and RSK1/2, respectively. PF-4708671 induces autophagy. First S6K1-specific inhibitor to be reported.

Selleck's PF-4708671 has been cited by 33 publications

Cell Death Dis, 2021, 12(1):108

PubMed: 33479203 ( click the link to review the publication )

Nat Commun, 2020, 11(1):3200

PubMed: 32581239 ( click the link to review the publication )

Cell Rep, 2020, 31(12):107800

PubMed: 32579927 ( click the link to review the publication )

Oncogene, 2020, 10.1038/s41388-020-01453-2

PubMed: 32917954 ( click the link to review the publication )

Oncogene, 2020, 10.1038/s41388-020-01497-4

PubMed: 33037411 ( click the link to review the publication )

Signal Transduct Target Ther, 2020, 5(1):153

PubMed: 32843616 ( click the link to review the publication )

Life Sci, 2020, 265:118848

PubMed: 33278383 ( click the link to review the publication )

Cell Mol Life Sci, 2020, 10.1007/s00018-020-03617-5

PubMed: 32804243 ( click the link to review the publication )

FASEB J, 2020, 10.1096/fj.202001183R

PubMed: 32686868 ( click the link to review the publication )

Viruses, 2020, 12(10)E1141

PubMed: 33050000 ( click the link to review the publication )

Nat Cell Biol, 2019, 21(6):778-790

PubMed: 31160710 ( click the link to review the publication )

Theranostics, 2019, 9(19):5464-5477

PubMed: 31534497 ( click the link to review the publication )

Oncogene, 2019, 38(35):6270-6282

PubMed: 31316145 ( click the link to review the publication )

Int J Mol Sci, 2019, 20(18)E4424

PubMed: 31505737 ( click the link to review the publication )

Platelets, 2019, 30(2):241-250

PubMed: 29257917 ( click the link to review the publication )

Virulence, 2018, 9(1):83-98

PubMed: 28475412 ( click the link to review the publication )

Nutr Metab (Lond), 2018, 10.1186/s12986-018-0268-9

PubMed: 29743930 ( click the link to review the publication )

NPJ Breast Cancer, 2018, 4:36

PubMed: 30456298 ( click the link to review the publication )

Cell Syst, 2017,

PubMed: 28017544 ( click the link to review the publication )

Cell Death Dis, 2017, 8(1):e2553

PubMed: 28079897 ( click the link to review the publication )

Front Immunol, 2017, 7:685

PubMed: 28138329 ( click the link to review the publication )

Clin Exp Allergy, 2017, 47(4):488-498

PubMed: 28000949 ( click the link to review the publication )

Oncotarget, 2016, 7(8):9163-74

PubMed: 26824321 ( click the link to review the publication )

Oncotarget, 2016, 7(32):52239-52254

PubMed: 27409169 ( click the link to review the publication )
Mol Cancer Ther, 2015, 14(3):799-809

PubMed: 25573956 ( click the link to review the publication )

J Immunol, 2015, 195(6):2529-39

PubMed: 26276876 ( click the link to review the publication )

J Biol Chem, 2015, 290(9):5592-605

PubMed: ( click the link to review the publication )

J Biol Chem, 2015, 290(9):5592-605

PubMed: 25561726 ( click the link to review the publication )

Toxicol Lett, 2015, 233(2):102-113

PubMed: 25597859 ( click the link to review the publication )

Cell Immunol, 2015, 298(1-2):9-17

PubMed: 26302934 ( click the link to review the publication )

Cell Signal, 2015, 27(11):2191-200

PubMed: 26210887 ( click the link to review the publication )

PLoS One, 2014, 9(2):e90388

PubMed: 24587347 ( click the link to review the publication )

Oncotarget, 2014, 5(10):3145-58

PubMed: 24762669 ( click the link to review the publication )

Purity & Quality Control

Choose Selective S6 Kinase Inhibitors

Biological Activity

Description

Targets

p70 S6K1 ^[1]
(Cell-free assay)

160 nM

In vitro

PF-4708671 is a piperazinyl-pyrimidine analogue and the first S6K1-specific inhibitor. PF-4708671 does not significantly inhibit the activity of the closely related S6K2 isoform or a number of other AGC kinases (Akt1, Akt2, PKA, PKCα, PKCϵ, PRK2, ROCK2, RSK1, RSK2 or SGK1) . PF-4708671 prevents the S6K1-mediated phosphorylation of S6 protein in response to IGF-1 (insulin-like growth factor 1), while having no effect upon the PMA-induced phosphorylation of substrates of the highly related RSK (p90 ribosomal S6 kinase) and MSK (mitogen- and stress-activated kinase) kinases. PF-4708671 is also found to induce phosphorylation of the T-loop and hydrophobic motif of S6K1, an effect that is dependent upon mTORC1 (mTOR complex 1). PF-4708671 does not affect activity of mTORC1. ^[1]

Cell Data

Cell Lines	Assay Type	Activity Description	PMID
BHT-101	MmnES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M4fNXWlEPTB;MD64NlAzPCEQvF2=	M3fNbHNCVkeHUh?=
UACC-893	NH\mfoZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NWDEdWR{UUN3ME21MlE6QDh4IN88US=>	NWHTeYxqW0GQR1XS
A427	NFvlUHlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NFXwU\|hKSzVyPUWuO\|I2PjdizszN	M1vJdHNCVkeHUh?=
OCUB-M	NHnwdGdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MkDrTWM2OD14Lk[2NVAzKM7:TR?=	MX3TRW5ITVJ?
SW684	M{G1RWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3ruWmlEPTB;Nz61NlI3QCEQvF2=	MVHTRW5ITVJ?
SK-LMS-1	MmLvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NUnqPG92UUN3ME25MlAyOzB{IN88US=>	MUnTRW5ITVJ?
CP50-MEL-B	MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NGTTe5RKSzVyPUmuN\|A1OTlizszN	NF;tSZlUSU6JRWK=
NCI-H1651	NVKxWYVzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M2TEPWlEPTB;MUCuNFI4PiEQvF2=	MmDsV2FPT0WU
ABC-1	NXr2dY4zT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NGj0cFBKSzVyPUGwMlExOzdizszN	M4\jcHNCVkeHUh?=
OE19	MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NEHBclhKSzVyPUGwMlE4OzNizszN	NYrySIpQW0GQR1XS
DSH1	NHnnbIVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NYe5ZYlzUUN3ME2xNE45QDd7IN88US=>	NID0NFdUSU6JRWK=
SW13	M3XkSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MUDJR\|UxRTFzLkmzNVkh\|ryP	M2jLOnNCVkeHUh?=
MDA-MB-453	MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1HJPWlEPTB;MUKuNVYxOyEQvF2=	MlTvV2FPT0WU
647-V	MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MVvJR\|UxRTF{LkO1PFIh\|ryP	MVfTRW5ITVJ?
NCI-H2342	NEPVdGtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NFPFNHVKSzVyPUGyMlM6QTVizszN	M1P2R3NCVkeHUh?=
LB2241-RCC	M{fGW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NVXQcnlrUUN3ME2xNk42Pzd7IN88US=>	MknXV2FPT0WU
UACC-257	NEnv[lRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MmixTWM2OD1zMz60OFU{KM7:TR?=	NWTpW2htW0GQR1XS
NCI-H661	M4izU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M{HkUGlEPTB;MUOuOlQ1QSEQvF2=	NInab5JUSU6JRWK=
FADU	MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MmnUTWM2OD1zMz62PVkzKM7:TR?=	M2HqbHNCVkeHUh?=
A2780	MlP4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MXXJR\|UxRTF\|LkiwOFEh\|ryP	M3TvR3NCVkeHUh?=
NCI-H1793	NEjNRnJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MVXJR\|UxRTF2LkSwPFUh\|ryP	MX;TRW5ITVJ?
TE-8	NUC4e4dwT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MoPHTWM2OD1zNT6zOFY2KM7:TR?=	MonyV2FPT0WU
HGC-27	M3u2S2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MlTXTWM2OD1zNj6xOlQ1KM7:TR?=	NUjmWW1bW0GQR1XS
MMAC-SF	MlriS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MkDrTWM2OD1zNz6zO\|I4KM7:TR?=	NEDOc4ZUSU6JRWK=
Calu-6	NVi1cm5ST3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MXPJR\|UxRTF6LkG1NVMh\|ryP	MkjYV2FPT0WU
HUTU-80	NGDBXoRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NFX5RpFKSzVyPUG4MlM6PTlizszN	M{jLbXNCVkeHUh?=
SAS	MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NVLMW217UUN3ME2xPE43PDV3IN88US=>	MXLTRW5ITVJ?
IST-MES1	M1Hrc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1vhZmlEPTB;MUiuOlUxQCEQvF2=	NX:5UphLW0GQR1XS
C3A	NUXPcXU2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NU\6WGF6UUN3ME2xPE44QTF7IN88US=>	NYTFUHpxW0GQR1XS
ES3	NV;hTFVPT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MUHJR\|UxRTF6LkizOlQh\|ryP	NHO0NVFUSU6JRWK=
HSC-2	NVrOPFdOT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MoTVTWM2OD1zOT62OVQyKM7:TR?=	MWTTRW5ITVJ?
T47D	NV23[FFWT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3O3NmlEPTB;MkCuNVQ5PSEQvF2=	NWn3T2Q1W0GQR1XS
EW-7	M2DV[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NXXGVHllUUN3ME2yNE45PTh6IN88US=>	MonKV2FPT0WU
LN-405	M1PidGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MnrTTWM2OD1{MD64PVY2KM7:TR?=	NX7hRZRVW0GQR1XS
U031	MkXiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NWXScoc{UUN3ME2yNU41QDB{IN88US=>	NXm2d5FPW0GQR1XS
A549	NVvZdXQzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NWLBd5duUUN3ME2yNU45PDlzIN88US=>	NUnNeo05W0GQR1XS
RMG-I	M2[0bmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Mn\QTWM2OD1{Mj6yOlY5KM7:TR?=	M37kZ3NCVkeHUh?=
BT-474	NULrVnczT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NEDydWFKSzVyPUKyMlY2PTFizszN	MYLTRW5ITVJ?
NB69	MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NFLEcI5KSzVyPUKzMlE2OiEQvF2=	MWHTRW5ITVJ?
NB7	MnfuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3rLT2lEPTB;MkSuNVg5KM7:TR?=	MUnTRW5ITVJ?
HCC1569	MmTiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M{TOfWlEPTB;MkSuOlEzPSEQvF2=	MUnTRW5ITVJ?
MEL-JUSO	M4raOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NXHlZoU2UUN3ME2yOE43QTB6IN88US=>	MWjTRW5ITVJ?
MDA-MB-175-VII	NWDHbFFQT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MmG2TWM2OD1{NT6yOVE4KM7:TR?=	NEf0OFVUSU6JRWK=
HCC1419	MmTaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MmnyTWM2OD1{NT62NFA{KM7:TR?=	M3X4ZnNCVkeHUh?=
Ca9-22	NVrnSIlRT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NYPJXXozUUN3ME2yOU43PDN{IN88US=>	M{Gze3NCVkeHUh?=
KGN	Mo\wS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NIfHUY5KSzVyPUK1Mlc2PDdizszN	NH;lNFRUSU6JRWK=
LB373-MEL-D	MmLUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NWnIPVhiUUN3ME2yOk4yQTN6IN88US=>	MVPTRW5ITVJ?
NCI-H1755	NVLqV2RYT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M4rXW2lEPTB;Mk[uPFg1OSEQvF2=	NHTyboFUSU6JRWK=
D-423MG	NHrLXWhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NVKwWItOUUN3ME2yO{4xPzF3IN88US=>	NYfUdJBPW0GQR1XS
DK-MG	M3rlTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NXi1XFFPUUN3ME2yPE44QDR4IN88US=>	MVfTRW5ITVJ?
NCI-H1623	Mk\mS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MYTJR\|UxRTJ6LkizOFIh\|ryP	MmXSV2FPT0WU
KU-19-19	NE\OTXNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NEL4SllKSzVyPUK4Mlk6PSEQvF2=	NFTnXVVUSU6JRWK=
C-33-A	MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MV;JR\|UxRTJ7LkKxPVgh\|ryP	MlXBV2FPT0WU
SCC-4	MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NXPuZmtwUUN3ME2zNE4{OzV2IN88US=>	MVvTRW5ITVJ?
MG-63	M365d2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NXzRVoJHUUN3ME2zNE42QTl2IN88US=>	MkLiV2FPT0WU
LNCaP-Clone-FGC	NFHsdYRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NVfWZ\|lwUUN3ME2zNU41QTJzIN88US=>	NVHDeWhiW0GQR1XS
CAPAN-1	MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MVnJR\|UxRTNzLkWyPFYh\|ryP	NW\YfoxpW0GQR1XS
GI-ME-N	MofFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MVPJR\|UxRTNzLkWzOVMh\|ryP	MkXLV2FPT0WU
RERF-LC-MS	MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NYLyXHpxUUN3ME2zNk43PzR5IN88US=>	MlP6V2FPT0WU
KLE	M2DJW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1TOXmlEPTB;M{OuOFM{PCEQvF2=	M2\HSHNCVkeHUh?=
KNS-81-FD	MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M{nhU2lEPTB;M{OuOVAxQCEQvF2=	M4OwNnNCVkeHUh?=
DOK	MnrkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NVTWW4hTUUN3ME2zOE43PjF{IN88US=>	MmjGV2FPT0WU
ACHN	M4PPb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NHLRO5ZKSzVyPUO1MlE2QDhizszN	MV3TRW5ITVJ?
KYSE-520	NGTvPWZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Ml7PTWM2OD1\|NT6yN\|YyKM7:TR?=	NXHKVI1yW0GQR1XS
SBC-5	NXTxTmRNT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NF;EXmhKSzVyPUO1MlUyOTZizszN	MlHhV2FPT0WU
NCI-H28	NEnVZ5RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MUfJR\|UxRTN3Lk[2PVUh\|ryP	NXHhe\|BzW0GQR1XS
ES7	MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NIfacnRKSzVyPUO2MlIzPDlizszN	MkjHV2FPT0WU
A172	MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MVnJR\|UxRTN4LkSxPFch\|ryP	Mmn3V2FPT0WU
UM-UC-3	NWH2TlByT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MXPJR\|UxRTN5Lki3OFYh\|ryP	MYnTRW5ITVJ?
LXF-289	MoroS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Mn;lTWM2OD1\|OD6wNFQ4KM7:TR?=	NFHP[JhUSU6JRWK=
KP-4	M2DORWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M{L5fmlEPTB;M{iuOFc{QSEQvF2=	NFzFb3hUSU6JRWK=
TE-1	M3\Nfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NHTKb5ZKSzVyPUO5MlY2QDlizszN	MV;TRW5ITVJ?
G-402	M2DEeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MmnFTWM2OD12MD6wOlEh\|ryP	MYHTRW5ITVJ?
786-0	NEP0OWpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NVHhdolHUUN3ME20NE46ODl4IN88US=>	NILzXYlUSU6JRWK=
K5	M{KxSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NGrZUXRKSzVyPUSxMlM3QDZizszN	NEnHPYxUSU6JRWK=
SK-N-DZ	NX7sfGlPT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mn3mTWM2OD12MT6zPFI{KM7:TR?=	NWjNdlVSW0GQR1XS
OVCAR-4	MnXBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NWnpUJNDUUN3ME20NU44PTZ6IN88US=>	MoPtV2FPT0WU
T84	NGS0SZRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MVLJR\|UxRTR{LkGyOlMh\|ryP	NIiyWW1USU6JRWK=
GCIY	M{\tXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NWLZWItqUUN3ME20N{4xQDB\|IN88US=>	NVSxc3JtW0GQR1XS
BB49-HNC	NFfCV\|FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3vidGlEPTB;NEOuN\|M1QCEQvF2=	MV\TRW5ITVJ?
SNU-C2B	MkHUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MVXJR\|UxRTR\|Lk[0N\|Yh\|ryP	NYDNRVZtW0GQR1XS
TE-6	NEfxO\|RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MYfJR\|UxRTR\|Lki4PVQh\|ryP	MlmzV2FPT0WU
23132-87	MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Ml7jTWM2OD12ND6yPVc5KM7:TR?=	M4P2[XNCVkeHUh?=
DMS-53	NH\QXXlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NYi3cZhyUUN3ME20OE4{Ozh2IN88US=>	NFv0bFhUSU6JRWK=
ONS-76	MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NGLkS4FKSzVyPUS0Mlc3PjFizszN	MUPTRW5ITVJ?
DMS-273	NXjKO3kzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NH\W[I9KSzVyPUS0Mlk1OyEQvF2=	Mn[3V2FPT0WU
COLO-824	M1P1Rmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NVi1fI9tUUN3ME20OU45Pzd3IN88US=>	MUnTRW5ITVJ?
DMS-114	NHe3RWVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NYLQXWk1UUN3ME20OU45QTJ5IN88US=>	NGrKe21USU6JRWK=
YKG-1	MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MVTJR\|UxRTR4LkCzOVUh\|ryP	M2LGS3NCVkeHUh?=
RH-18	NFXldZNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MYHJR\|UxRTR4LkO3N\|Mh\|ryP	MX\TRW5ITVJ?
NCI-H1355	NI\MU21Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NGHnTXpKSzVyPUS2MlYyQCEQvF2=	NWjzZVE2W0GQR1XS
NCI-H2170	Mnn2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NVO2NGhvUUN3ME20O{44PTh2IN88US=>	Ml7YV2FPT0WU
OC-314	NUXWcYR{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MkLlTWM2OD12Nz64OFc5KM7:TR?=	Mn7TV2FPT0WU
NCI-H2030	NWjXTWhnT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M2LYSmlEPTB;NEeuPFkxPiEQvF2=	NIPBS\|VUSU6JRWK=
22RV1	MlnNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NFvrO5BKSzVyPUS3MlkxOTVizszN	M4rKUXNCVkeHUh?=
G-401	M3zLWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MkLMTWM2OD12OD60OFE2KM7:TR?=	MmrnV2FPT0WU
YAPC	MkfQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Ml:xTWM2OD12OT64NFc{KM7:TR?=	MmnKV2FPT0WU
SW1573	Ml70S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NV\PNmNTUUN3ME21NE4zPDN3IN88US=>	NHHGdGtUSU6JRWK=
COLO-792	NETnWINIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NFzJOFBKSzVyPUWwMlYzOzdizszN	NEHsW41USU6JRWK=
KNS-62	NF;MUmdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MVzJR\|UxRTVyLke1NFgh\|ryP	M4PRR3NCVkeHUh?=
NB5	MlTwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NWLsRo53UUN3ME21NU41PTB7IN88US=>	NUK2XIlMW0GQR1XS
CP66-MEL	Mnu0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NV3sbpJbUUN3ME21NU43PDB6IN88US=>	MmWxV2FPT0WU
CaR-1	NV7JWlk5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MX3JR\|UxRTV{LkC2NFYh\|ryP	NUnve\|ZLW0GQR1XS
CAL-54	MnvaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MWLJR\|UxRTV{LkGxNFIh\|ryP	NFTpdI1USU6JRWK=
8305C	M3n2T2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MYLJR\|UxRTV{LkOxOUDPxE1?	MUDTRW5ITVJ?
Calu-3	MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MkH6TWM2OD13Mj6zO\|M{KM7:TR?=	MYrTRW5ITVJ?
AU565	NIXhW3hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MWPJR\|UxRTV{LkW1NFkh\|ryP	MXfTRW5ITVJ?
CW-2	MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NIWyfm9KSzVyPUWyMlg3PTRizszN	MVvTRW5ITVJ?
BEN	NFH5VXJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NYjje4dFUUN3ME21N{44QDZ{IN88US=>	M1L3UHNCVkeHUh?=
NCI-H1975	MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NWj3TIpIUUN3ME21N{45QTZ4IN88US=>	M{LNWXNCVkeHUh?=
HCT-116	M363Wmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3\pUmlEPTB;NUSuNFMzPyEQvF2=	MofhV2FPT0WU
SH-4	MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M{LHb2lEPTB;NUSuNVM5KM7:TR?=	NX3JRphIW0GQR1XS
NCI-H1693	NULkVXJLT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NFjWS2dKSzVyPUW0MlIyODNizszN	MYXTRW5ITVJ?
BPH-1	Mn;RS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M13MPGlEPTB;NUWuNlg6OiEQvF2=	NWOxNVAxW0GQR1XS
CAMA-1	NFq3Sm1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1;BOmlEPTB;NUWuPFEyPiEQvF2=	MUjTRW5ITVJ?
A388	NETEPFJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NYDid2lCUUN3ME21Ok4xQTh3IN88US=>	NIHRd2dUSU6JRWK=
C2BBe1	M2H5e2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NE\mbHZKSzVyPUW2MlI3OzRizszN	NWLh[m5UW0GQR1XS
GAMG	MnTpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3\BeGlEPTB;NU[uOVk2PSEQvF2=	MlrmV2FPT0WU
MKN28	MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MmC5TWM2OD13Nj64NFE{KM7:TR?=	NFfKSllUSU6JRWK=
VA-ES-BJ	MkPHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NVL5OmRUUUN3ME21Ok45PzR3IN88US=>	NXL6S3luW0GQR1XS
HuCCT1	NUHncJhkT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NU\nZ\|h5UUN3ME21O{4xPDl{IN88US=>	MYXTRW5ITVJ?
BFTC-905	MnzXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MnHuTWM2OD13Nz6yPFk5KM7:TR?=	MoXyV2FPT0WU
LS-123	MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MnvKTWM2OD13Nz61OlY5KM7:TR?=	NHLnTGlUSU6JRWK=
LB996-RCC	MkjLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3nsbWlEPTB;NUiuNFI5PyEQvF2=	M4KxbXNCVkeHUh?=
NCI-H1048	MmHxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MojTTWM2OD13OD6yNVg5KM7:TR?=	NWHWTWRQW0GQR1XS
COR-L105	NILuSGdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MkLUTWM2OD13OD63N\|M4KM7:TR?=	MXXTRW5ITVJ?
OVCAR-8	M{juemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NVHpdo1kUUN3ME21PU4yPzF4IN88US=>	NGq0RohUSU6JRWK=
SK-N-FI	MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1fPUWlEPTB;NUmuN\|IxPyEQvF2=	MYnTRW5ITVJ?
MES-SA	M3rtT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MmrKTWM2OD13OT60OVA6KM7:TR?=	NYjxUGx7W0GQR1XS
SCC-9	MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NH3JSHpKSzVyPUW5MlQ4PTNizszN	M{nXdnNCVkeHUh?=
EFO-27	NFjQU2FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NIDPSJNKSzVyPUW5Mlk1OyEQvF2=	MkfiV2FPT0WU
GT3TKB	MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MUnJR\|UxRTZyLk[wOFgh\|ryP	NIG4TVFUSU6JRWK=
HCC38	NHviNYtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MVPJR\|UxRTZzLkSzO\|kh\|ryP	NVHMb5hiW0GQR1XS
MLMA	MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NVrR[4FSUUN3ME22NU43OTZ\|IN88US=>	M3LRZXNCVkeHUh?=
D-566MG	MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M{nyTmlEPTB;NkOuOVIzPCEQvF2=	MX7TRW5ITVJ?
SF295	M1;YXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NVPZfpBGUUN3ME22N{43PjV3IN88US=>	M1KxVXNCVkeHUh?=
ES4	MoXFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NFLCc25KSzVyPU[0MlQ4OTlizszN	MYLTRW5ITVJ?
CAKI-1	MoLHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NYDvdXlqUUN3ME22OE42PzJzIN88US=>	NF3HdZNUSU6JRWK=
OAW-28	NEnkO4RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MVTJR\|UxRTZ2Lkm2OFch\|ryP	MnLxV2FPT0WU
NCI-H460	MmP1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NVnMS5IxUUN3ME22OU4xQDl5IN88US=>	NVvzUFNRW0GQR1XS
JAR	M4Lafmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M2XNSmlEPTB;NkWuOVUyPiEQvF2=	M2\TWnNCVkeHUh?=
SNU-449	NI\nXnRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NXrxeXl7UUN3ME22OU44PjF4IN88US=>	MVjTRW5ITVJ?
D-392MG	NWThSVA2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NHHCZllKSzVyPU[1Mlk1OzRizszN	NVXGV3lCW0GQR1XS
EW-22	NULPe2ZjT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MWPJR\|UxRTZ4LkO5OUDPxE1?	MmjrV2FPT0WU
GCT	M2DoO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NUfUeZpoUUN3ME22O{4xPDR\|IN88US=>	NHnB[VVUSU6JRWK=
NOS-1	Moj6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MUnJR\|UxRTZ5Lk[4Olch\|ryP	NH\JT5ZUSU6JRWK=
RH-1	NY[1ZXlYT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M{jmdmlEPTB;NkiuOVU2QSEQvF2=	MYrTRW5ITVJ?
HuH-7	NG\HdWtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MUfJR\|UxRTZ7LkGwNFIh\|ryP	MVTTRW5ITVJ?
NUGC-3	MlWyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1O3XGlEPTB;N{CuPVY1PCEQvF2=	NHfHbW9USU6JRWK=
IST-SL1	MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NULXXm1jUUN3ME23NU4zOzJ2IN88US=>	M3HkfnNCVkeHUh?=
SHP-77	M3uxcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NVn6[XlOUUN3ME23Nk4yOTlizszN	NGO3OZFUSU6JRWK=
SW1116	NVjnS5NQT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MmfNTWM2OD15Mj6xOFA4KM7:TR?=	NIq3dm5USU6JRWK=
LK-2	NWraXJZOT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MlXsTWM2OD15Mj64OlEzKM7:TR?=	MYHTRW5ITVJ?
U-2-OS	NXPad4pYT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NWO4UVlQUUN3ME23N{4yQDJ6IN88US=>	MX;TRW5ITVJ?
KYSE-150	MkLlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MVHJR\|UxRTd\|Lk[xNVgh\|ryP	NXXYPGw6W0GQR1XS
U251	NYXa[ZBST3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3qydGlEPTB;N{OuPFE3QCEQvF2=	NEPqWphUSU6JRWK=
HT-1080	M4HBbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M4XoS2lEPTB;N{SuNlU4PCEQvF2=	NIHie\|VUSU6JRWK=
NCI-H1437	MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MX3JR\|UxRTd2Lk[zNlYh\|ryP	MkDOV2FPT0WU
HPAF-II	MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NV[0blFZUUN3ME23OE43PDF3IN88US=>	MX;TRW5ITVJ?
Becker	NYLCO4E2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MWnJR\|UxRTd3LkGxNFUh\|ryP	MW\TRW5ITVJ?
PANC-10-05	MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MUfJR\|UxRTd3LkK4OlUh\|ryP	NG\KcZlUSU6JRWK=
TYK-nu	NEPZVJlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MXLJR\|UxRTd3LkOxNFIh\|ryP	MWPTRW5ITVJ?
SKG-IIIa	NIm4W5BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NG\lVFBKSzVyPUe1MlM{PDFizszN	MXjTRW5ITVJ?
NCI-H1993	NFHIWotIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NGizOIJKSzVyPUe1Mlc{QTdizszN	NWDhVGVvW0GQR1XS
S-117	MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MYrJR\|UxRTd3Lke1OUDPxE1?	MmDXV2FPT0WU
HuO9	NWrnVnl{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NWDjTnU6UUN3ME23Ok4xODR6IN88US=>	NEHjdnNUSU6JRWK=
CAL-51	MknSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NWXWZXdFUUN3ME23Ok4yODB4IN88US=>	MVXTRW5ITVJ?
BT-20	M1PhZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NILF[llKSzVyPUe2MlIyPjhizszN	NVHYPJI6W0GQR1XS
LB831-BLC	MnL5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MYfJR\|UxRTd4LkOyNVch\|ryP	Mn;GV2FPT0WU
LB1047-RCC	NXrCR2tFT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NXzkbph1UUN3ME23Ok44PjF7IN88US=>	NID2cZpUSU6JRWK=
ES8	NUf5XmdxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MWnJR\|UxRTd6LkCwO\|Mh\|ryP	NYTvVJRJW0GQR1XS
UMC-11	MoXmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MXXJR\|UxRTd6LkC4PFQh\|ryP	M4ewcXNCVkeHUh?=
NCI-H226	NEnyVJpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MWHJR\|UxRTd6LkGzNVUh\|ryP	MlnwV2FPT0WU
IGROV-1	NVewXI5uT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MkOyTWM2OD15OD61OVUh\|ryP	NGTLVYdUSU6JRWK=
BHY	MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NH;hdGxKSzVyPUe5MlU6PiEQvF2=	NVjrTHdCW0GQR1XS
MKN45	MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NEDVPY9KSzVyPUiwMlMyPzRizszN	MYnTRW5ITVJ?
IA-LM	NVX0fmtCT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3LQXGlEPTB;OECuN\|UyOSEQvF2=	NFPLdFBUSU6JRWK=
WM-115	NXznT4dPT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MUfJR\|UxRThzLkSxNVQh\|ryP	MWrTRW5ITVJ?
VMRC-RCZ	NIHq[YpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MUDJR\|UxRThzLkS0NlUh\|ryP	NUi1dmdtW0GQR1XS
NCI-H2291	NXTEOHVPT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3PKTGlEPTB;OEGuOlg1OiEQvF2=	MYPTRW5ITVJ?
MCF7	M3\teWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Mof6TWM2OD16Mz6yPFk4KM7:TR?=	M3\rRXNCVkeHUh?=
639-V	MlG4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3L3eGlEPTB;OESuOlEzQSEQvF2=	Mmn4V2FPT0WU
RT4	NXjwcnczT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NHjabY1KSzVyPUi1MlI1ODNizszN	NYPsZ\|R5W0GQR1XS
NCI-H2405	Mmi5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3XMXmlEPTB;OEWuNlk6PyEQvF2=	NIX6[XZUSU6JRWK=
CAL-33	MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3K0SWlEPTB;OEWuOlMyPSEQvF2=	M2PWdHNCVkeHUh?=
BT-549	MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NFHRPWpKSzVyPUi1Mlk{QDJizszN	M4jjdXNCVkeHUh?=
HT-1197	NGLWNlVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NUC0OHB2UUN3ME24PE4yODd5IN88US=>	MorOV2FPT0WU
G-361	MoLxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M4\LeGlEPTB;OEiuNVQ4PCEQvF2=	MXrTRW5ITVJ?
LS-411N	MmHzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MXPJR\|UxRTh7LkOzPFgh\|ryP	NF[0[4pUSU6JRWK=
HT-144	MnjTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MlzSTWM2OD16OT61PVkzKM7:TR?=	M3XHeHNCVkeHUh?=
DJM-1	NVO2N4lpT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MVnJR\|UxRTh7Lki4OFUh\|ryP	NXTsOZpOW0GQR1XS
CAL-12T	MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NFi4eY5KSzVyPUmwMlc5QTVizszN	NH:3N5VUSU6JRWK=
MKN7	M3jGcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MYPJR\|UxRTlzLkO1OVEh\|ryP	M{W0cnNCVkeHUh?=
HuP-T3	Moj4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NVvtR\|RWUUN3ME25Ok4yODB2IN88US=>	M4XZUHNCVkeHUh?=
SK-MG-1	MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NV\I[mJFUUN3ME25Ok4yOzR6IN88US=>	NYPpbWZSW0GQR1XS
NCI-H2347	NYnrcJczT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NHG2WXlKSzVyPUm4MlExPDJizszN	NYjlPHhbW0GQR1XS
SW872	M1zLSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NXnLT2tzUUN3ME2xNFAvPDV4IN88US=>	MUnTRW5ITVJ?
COLO-829	M1PpfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NETZ[3lKSzVyPUGwNE42PTNizszN	M4\UfHNCVkeHUh?=
MC-IXC	MoHGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NX;Ed2U6UUN3ME2xNFAvPjF3IN88US=>	NILhOIJUSU6JRWK=

... Click to View More Cell Line Experimental Data

Assay

Methods	Test Index	PMID
Western blot	pS6 / S6 / pS6K / S6K1 / pAKT / AKT ; PubMed: 28626016 J Neurosci Western blot of cell lysates from neurons treated with PF-4708671, rapamycin, and Torin-2, individually or in combination for the indicated times. p-mTOR / mTOR / p-p70S6K / p70S6K ; PubMed: 30423811 Int J Mol Sci As determined using Western blotting, the phospho-p70S6K (p-p70S6K) inhibitor (PF-4708671) reduced the expression of phospho-mTOR (p-mTOR) and p-p70S6K in SCC-4 and SCC-25 cells. SCC-4 and SCC-25 cells were not treated as negative control (NC) or treated with 20 µM PF-4708671 for 6 h (6 h), 12 h (12 h), 18 h (18 h), 1 day (1 d), 2 days (2 d), and 3 days (3 d). Western blot analysis was performed to examine the expression levels of p-mTOR, mTOR, p-p70S6K, p70S6K, and β-actin.	28626016 30423811
Growth inhibition assay	Cell viability; PubMed: 30423811 Int J Mol Sci Inhibitory effects of various doses (0.5, 1, 2, 5, 10, 20, and 40 µM) of PF-4708671 on SCC-4 (B) and SCC-25 (C) cells were assessed using MTT assay after 72 h of treatment. Data presented are the mean and standard error of the mean of three independent experiments. * p < 0.05, p < 0.01, and * p < 0.001 indicate the statistical significance of differences between cells with and without treatment. t (red and * for SCC-4 and blue , * and *** for SCC-25).	30423811

Protocol

References

[1] Pearce LR, et al. Biochem J, 2010, 431(2), 245-255.

Solubility (25°C)

In vitro	DMSO	30 mg/mL (76.84 mM)
	Ethanol	8 mg/mL (20.49 mM)
	Water	Insoluble
In vivo	Add solvents to the product individually and in order(Data is from Selleck tests instead of citations): 30% PEG400+0.5% Tween80+5% propylene glycol For best results, use promptly after mixing.	30 mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information Download PF-4708671 SDF

Molecular Weight	390.41
Formula	C₁₉H₂₁F₃N₆
CAS No.	1255517-76-0
Storage	3 years-20°C powder 2 years-80°C in solvent
Synonyms	N/A
Smiles	CCC1=CN=CN=C1N2CCN(CC2)CC3=NC4=C(N3)C=C(C=C4)C(F)(F)F

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

Dosage

mg/kg

Average weight of animals

Dosing volume per animal

Number of animals

Step 2: Enter the in vivo formulation (Different batches have different solubility ratios, please contact Selleck to provide you with the correct ratio)

% DMSO+ % + % Tween 80+ % ddH₂O

Calculate Reset

Calculation results:

Working concentration： mg/ml；

Method for preparing DMSO master liquid: ： mg drug pre-dissolved in μL DMSO (Master liquid concentration mg/mL， Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation：Take μL DMSO master liquid, next addμL PEG300， mix and clarify, next addμL Tween 80，mix and clarify, next add μL ddH₂O，mix and clarify.

Note：1.Please make sure the liquid is clear before adding the next solvent.
2.Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.

Bio Calculators

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

Serial Dilutions
Concertration (start):
Dilution-folds:

Computed Result

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Frequently Asked Questions

Question 1:
Whether the in vivo formula "30% PEG400+0.5% Tween80+5% Propylene glycol" for S2163 is suitable for i.p. or not?
Answer:
The formula "30% PEG400+0.5% Tween80+5% Propylene glycol" on our website is an oral one. It is a suspension.

S6 Kinase Signaling Pathway Map

Related S6 Kinase Products

LY2584702 ^New

LY2584702 is a selective, ATP-competitive p70S6K inhibitor with IC50 of 4 nM. Phase 1.
LY2584702 Tosylate ^New

LY2584702 Tosylate is a selective, ATP-competitive p70S6K inhibitor with IC50 of 4 nM. Phase 1.
CHIR-99021 (CT99021) ^New

CHIR-99021 (CT99021) is a GSK-3α and GSK-3β inhibitor with IC50 of 10 nM and 6.7 nM, respectively. CHIR99201 does not exhibit cross-reactivity against cyclin-dependent kinases (CDKs) and shows a 350-fold selectivity toward GSK-3β compared to CDKs. CHIR99021 functions as a Wnt/β-catenin activator and induces autophagy.
BI-D1870

BI-D1870 is an ATP-competitive inhibitor of S6 ribosome for RSK1/2/3/4 with IC50 of 31 nM/24 nM/18 nM/15 nM in cell-free assays, respectively; 10- to 100-fold selectivity for RSK than MST2, GSK-3β, MARK3, CK1 and Aurora B. BI-D1870 exhibits anticancer attributes including the generation of reactive oxygen species (ROS) and increases in endoplasmic reticulum (ER) stress and autophagy.
Rapamycin (Sirolimus)

Rapamycin (Sirolimus, AY 22989, NSC-2260804) is a specific mTOR inhibitor with IC50 of ~0.1 nM HEK293 cells.
MK-2206 2HCl

MK-2206 2HCl is a highly selective inhibitor of Akt1/2/3 with IC50 of 8 nM/12 nM/65 nM in cell-free assays, respectively; no inhibitory activities against 250 other protein kinases observed. MK-2206 2HCl induces autophagy and apoptosis in cancer cells. Phase 2.

Features:The first allosteric small molecule inhibitor of Akt to enter clinical development.
CHIR-99021 (CT99021) HCl

CHIR-99021 (CT99021) HCl is hydrochloride of CHIR-99021, which is a GSK-3α/β inhibitor with IC50 of 10 nM/6.7 nM; CHIR-99021 shows greater than 500-fold selectivity for GSK-3 versus its closest homologs Cdc2 and ERK2. CHIR-99021 is a potent pharmacological activators of the Wnt/beta-catenin signaling pathway. CHIR-99021 significantly rescues light-induced autophagy and augments GR, RORα and autophagy-related proteins.
LY294002

LY294002 (SF 1101, NSC 697286) is the first synthetic molecule known to inhibit PI3Kα/δ/β with IC50 of 0.5 μM/0.57 μM/0.97 μM, respectively; more stable in solution than Wortmannin, and also blocks autophagosome formation. It not only binds to class I PI3Ks and other PI3K-related kinases, but also to novel targets seemingly unrelated to the PI3K family. LY294002 also inhibits CK2 with IC50 of 98 nM. LY294002 is a non-specific DNA-PKcs inhibitor and activates autophagy and apoptosis.
3-Methyladenine (3-MA)

3-Methyladenine (3-MA, NSC 66389) is a selective PI3K inhibitor for Vps34 and PI3Kγ with IC50 of 25 μM and 60 μM in HeLa cells; blocks class I PI3K consistently, whereas suppression of class III PI3K is transient, and also blocks autophagosome formation. 3-Methyladenine (3-MA) is successfully used to suppress mitophagy. Solutions of 3-MA are best fresh-prepared by heating.
Everolimus (RAD001)

Everolimus (RAD001, SDZ-RAD) is an mTOR inhibitor of FKBP12 with IC50 of 1.6-2.4 nM in a cell-free assay. Everolimus induces cell apoptosis and autophagy and inhibits tumor cells proliferation.

Choose Your Country or Region

By Signaling Pathways

By product type

PF-4708671